Search
Log in
Join
Experiences with
Arzerra
Posts
Communities
18 public posts
Filter results
Arzerra for Marginal Zone B Cell Lymphoma
She is now trying
Arzerra
. Wondering if anyone has had
Arzerra
as a treatment for this as what I read shows it as a treatment for CLL.
She is now trying
Arzerra
. Wondering if anyone has had
Arzerra
as a treatment for this as what I read shows it as a treatment for CLL.
Supporting my grandmother
Just wondered if anyone else had had
Arzerra
for lymphoma rather than CLL.
Just wondered if anyone else had had
Arzerra
for lymphoma rather than CLL.
Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival (PFS) compared with ofatumumab (
Arzerra
) while producing rapid and durable responses in heavily pretreated patients.
Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival (PFS) compared with ofatumumab (
Arzerra
) while producing rapid and durable responses in heavily pretreated patients.
Want to take advantage of all our features? Just log in!
Log in
or
Join
FDA Approves Duvelisib for CLL and Follicular Lymphoma - Sep 24, 2018
In DUO, duvelisib reduced the risk of disease progression or death by 60% versus ofatumumab (
Arzerra
) in patients with relapsed/refractory CLL/SLL who had received at least 2 prior lines of therapy.
In DUO, duvelisib reduced the risk of disease progression or death by 60% versus ofatumumab (
Arzerra
) in patients with relapsed/refractory CLL/SLL who had received at least 2 prior lines of therapy.
Verastem, with Phase 3 Results, to Request FDA Approve Oral Duvelisib to Treat Advanced CLL and SLL
This was 3.4 months longer than in patients treated with
Arzerra
. Source: http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-newsArticle&ID=2298616
This was 3.4 months longer than in patients treated with
Arzerra
. Source: http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-newsArticle&ID=2298616
Duvelisib Drug Succeeds in Late-Stage Trial
Here is a paragraph from the writeup: "Verastem's drug, Duvelisib, showed a superior progression-free survival rate than the current standard of care, Novartis's
Arzerra
(ofatumumab), when tested on patients suffering from cancers that affect cells of the immune system, Verastem said."
Here is a paragraph from the writeup: "Verastem's drug, Duvelisib, showed a superior progression-free survival rate than the current standard of care, Novartis's
Arzerra
(ofatumumab), when tested on patients suffering from cancers that affect cells of the immune system, Verastem said."
Dr Susan O'Brien Sheds Light on Role of Next-Generation Agents in CLL
[/i] OncLive interview with Dr O'Brien: http://global.onclive.com/web-exclusives/expert-sheds-light-on-role-of-nextgeneration-agents-in-cll Drugs mentioned: ibrutinib (Imbruvica) idelalisib (Zydelig) duvelisib in trial versus ofatumumab (
Arzerra
) TGR-1202 (PI3K inhibitor) acalabrutinib, (ACP-196) a
[/i] OncLive interview with Dr O'Brien: http://global.onclive.com/web-exclusives/expert-sheds-light-on-role-of-nextgeneration-agents-in-cll Drugs mentioned: ibrutinib (Imbruvica) idelalisib (Zydelig) duvelisib in trial versus ofatumumab (
Arzerra
) TGR-1202 (PI3K inhibitor) acalabrutinib, (ACP-196) a
Arzerra (ofatumumab) PBS listed in Australia
[/i] http://www.pharmacydaily.com.au/news/
arzerra
-pbs-listed/41548 This news even made the National 7 News, which gave a good overview of CLL and included a brief interview with Dr Con Tam. Neil
[/i] http://www.pharmacydaily.com.au/news/
arzerra
-pbs-listed/41548 This news even made the National 7 News, which gave a good overview of CLL and included a brief interview with Dr Con Tam. Neil
Biologic or Immune Therapies for CLL
These include rituximab (Rituxan), ofatuzumab (
Arzerra
), and obinituzumab (Gazyva). Among other topics, I discuss the difference between type I and type II monoclonal antibodies.
These include rituximab (Rituxan), ofatuzumab (
Arzerra
), and obinituzumab (Gazyva). Among other topics, I discuss the difference between type I and type II monoclonal antibodies.
UK - NICE Guidance for NHS use of Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia -
Two buses arrive at the same time on the same day making new treatments available to NHS England & Wales CLL patients Technology appraisal guidance [TA344] Published date: June 2015 You can access full guidance details on the NICE website here: http://www.nice.org.uk/guidance/ta344 [i]Ofatumumab (
Arzerra
Two buses arrive at the same time on the same day making new treatments available to NHS England & Wales CLL patients Technology appraisal guidance [TA344] Published date: June 2015 You can access full guidance details on the NICE website here: http://www.nice.org.uk/guidance/ta344 [i]Ofatumumab (
Arzerra
Ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland.
Ofatumumab (
Arzerra
) [i]
Advice
following a full submission assessed under the orphan process ofatumumab (
Arzerra
®) is accepted for restricted use within NHS Scotland.
Ofatumumab (
Arzerra
) [i]
Advice
following a full submission assessed under the orphan process ofatumumab (
Arzerra
®) is accepted for restricted use within NHS Scotland.
My husband is on Arzerra (Ofatumumab) for CLL and he has had 2 treatments. Any suggestions on lethargy and weakness as side effects?
Marketing authorisation application submitted to the European Medicines Agency for the use of ofatumumab for first line treatment
GlaxoSmithKline plc and Genmab A/S have submitted a variation to the marketing authorisation application (MAA) to the European Medicines Agency (EMA) for the use of
Arzerra
(ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of Chronic Lymphocytic Leukaemia (CLL) patients
GlaxoSmithKline plc and Genmab A/S have submitted a variation to the marketing authorisation application (MAA) to the European Medicines Agency (EMA) for the use of
Arzerra
(ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of Chronic Lymphocytic Leukaemia (CLL) patients
Update on Novel B-Cell Receptor Signaling Inhibitors from NCCN 8th Annual Congress on Hematologic Malignancies
Brief mention is also made of the benefits observed when using Ibrutinib with Ofatumumab (
Arzerra
) and rituximab.
Brief mention is also made of the benefits observed when using Ibrutinib with Ofatumumab (
Arzerra
) and rituximab.
Arzerra(R) (Ofatumumab) granted FDA 'Breakthrough Therapy Designation' for Previously Untreated CLL
Source http://www.gsk.com/media/press-releases/2013/fda-grants-gsk-and-genmabs-
arzerra
---ofatumumab--breakthrough-th.html
Source http://www.gsk.com/media/press-releases/2013/fda-grants-gsk-and-genmabs-
arzerra
---ofatumumab--breakthrough-th.html
Genmab Announces Top-Line Phase II Results for Ofatumumab Combined with Bendamustine in Untreated and Relapsed CLL
ReleaseID=760980 Note:
ARZERRA
is not approved for the treatment of untreated CLL anywhere in the world. It is approved for use in fludarabine refractory CLL, in the US and EU
ReleaseID=760980 Note:
ARZERRA
is not approved for the treatment of untreated CLL anywhere in the world. It is approved for use in fludarabine refractory CLL, in the US and EU
CLL - a Cancer of the Immune System
temperature should be treated seriously, particularly if you are having treatment or have been treated with a CD20 monoclonal antibody such as Rituximab/Rituxan/Mabthera, Obinutuzumab/Gazyva or Ofatumumab/
Arzerra
within the last year, where you may be experiencing Late Onset Neutropenia https://healthunlocked.com
temperature should be treated seriously, particularly if you are having treatment or have been treated with a CD20 monoclonal antibody such as Rituximab/Rituxan/Mabthera, Obinutuzumab/Gazyva or Ofatumumab/
Arzerra
within the last year, where you may be experiencing Late Onset Neutropenia https://healthunlocked.com
Arzerra (ofatumumab) approved in Japan for CLL
"We are pleased that patients in Japan will now have access to
Arzerra
. Japan is another important market for
Arzerra
and commercialization continues on track," said Jan van de Winkel, Ph.D. Chief Executive Officer of Genmab.
"We are pleased that patients in Japan will now have access to
Arzerra
. Japan is another important market for
Arzerra
and commercialization continues on track," said Jan van de Winkel, Ph.D. Chief Executive Officer of Genmab.
Filter results
Clear filters
Posted in
All communities
CLL Support
17 results
Non Hodgkin's Lymphoma Friends
1 result
Sort by
Most Relevant
Newest
